Clinical Trial Update: Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma [Phase 1]

View source ↗

Summary

Clinical trial update for a Phase 1 study of a personalized neoantigen DNA vaccine in combination with retifanlimab PD-1 blockade for newly diagnosed unmethylat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Personalized neoantigen DNA vaccine
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Unmethylated Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING